BillionToOne, Inc. (BLLN)
| Market Cap | 5.38B |
| Revenue (ttm) | 397.41M +90.1% |
| Net Income | 33.18M |
| EPS | 0.77 |
| Shares Out | 47.19M |
| PE Ratio | 148.24 |
| Forward PE | 155.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 453,431 |
| Open | 113.96 |
| Previous Close | 114.07 |
| Day's Range | 113.11 - 119.20 |
| 52-Week Range | 61.96 - 150.44 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 129.00 (+13.16%) |
| Earnings Date | Nov 4, 2026 |
About BLLN
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for BLLN stock is "Buy." The 12-month stock price target is $129.0, which is an increase of 13.16% from the latest price.
News
BillionToOne to Participate in Two Upcoming Investor Conferences
MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are a...
BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are a...
BillionToOne publishes Northstar Response head-to-head study
BillionToOne (BLLN) announced the publication of the first peer-reviewed head-to-head study comparing Northstar Response, a tissue-free, methylation-based liquid biopsy assay utilizing patented single...
BillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds
Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response Head-to-head comparison shows 94% ...
BillionToOne price target raised to $128 from $125 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on BillionToOne (BLLN) to $128 from $125 and keeps a Buy rating on the shares. The firm adjusted its models and…
BillionToOne Transcript: Wells Fargo 21st Annual Healthcare Conference
Q2 saw 64% revenue growth and profitability, driven by strong performance in both prenatal and oncology. Expansion into health systems and product innovation are set to accelerate growth, while reimbursement improvements and high-margin strategies support long-term profitability.
BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are acces...
BillionToOne initiated with a Buy at Canaccord
Canaccord analyst Kyle Mikson initiated coverage of BillionToOne (BLLN) with a Buy rating and $120 price target The company’s single-molecule next-generation sequencing and quantitative counting templ...
BillionToOne announces the launch of Northstar Origin
BillionToOne (BLLN) announced the launch of Northstar Origin, a new liquid biopsy add-on test for tissue-of-origin prediction, along with the expansion of its Northstar Select panel from 84 to 102…
BillionToOne launches Northstar Origin, a new liquid biopsy test
BillionToOne (BLLN) announced the launch of Northstar Origin, a new liquid biopsy add-on test for tissue-of-origin prediction, along with the expansion of its Northstar Select panel from 84 to 102…
BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin
New add-on test from a single blood draw; BillionToOne also expands Northstar Select® panel to 102 genes MENLO PARK, Calif., Sept. 1, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-gen...
BillionToOne announces publication of study on cfDNA fetal risk assessment
BillionToOne (BLLN) announced publication of A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population in The Green...
Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions
Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results ME...
BillionToOne falls -38.3%
BillionToOne (BLLN) is down -38.3%, or -$57.46 to $92.51.
BillionToOne falls -36.7%
BillionToOne (BLLN) is down -36.7%, or -$54.97 to $95.00.
BillionToOne price target lowered to $130 from $145 at JPMorgan
JPMorgan analyst Casey Woodring lowered the firm’s price target on BillionToOne (BLLN) to $130 from $145 and keeps an Overweight rating on the shares. The company reported a “bit of…
BillionToOne price target lowered to $130 from $142 at BTIG
BTIG lowered the firm’s price target on BillionToOne (BLLN) to $130 from $142 and keeps a Buy rating on the shares. Shares declined after an in-line quarter impacted by one-time…
BillionToOne reports Q2 EPS 15c, consensus 16c
Reports Q2 revenue $109.45M, consensus $109.12M. “Our second quarter demonstrated the durability of our model, with our differentiated technology platform, category-defining products, and disciplined ...
BillionToOne backs FY26 revenue view $450M-$465M, consensus $454.14M
The company said, “BillionToOne (BLLN) continues to expect full year 2026 total revenue of $450.0 million to $465.0 million, representing growth of 48% to 52% compared to full year 2025.
BillionToOne Earnings Call Transcript: Q2 2026
Q2 2026 saw 64% year-over-year revenue growth to $109.4 million, with gross margin above 70% and strong gains in both prenatal and oncology. New product launches, rapid health system integrations, and robust cash flow position the company for continued growth and profitability.
BillionToOne Slides: Q2 2026
BillionToOne has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
BillionToOne Earnings release: Q2 2026
BillionToOne released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
BillionToOne Quarterly report: Q2 2026
BillionToOne has published its Q2 2026 quarterly earnings report on August 5, 2026.
BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are a...
BillionToOne appoints Ethan Dmitrovsky as Chief Medical Officer
BillionToOne (BLLN) announced the appointment of Ethan Dmitrovsky, one of the most accomplished and influential physician leaders in oncology, as Chief Medical Officer, Oncology. Dmitrovsky will lead ...